From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
Many pharmaceutical manufacturers struggle to stay on top of State Price Transparency legislation. IntegriChain Operational Consulting provides the expertise to keep manufacturers compliant and informed.
State Price Transparency legislation is an initiative by state agencies to increase public awareness around the Wholesale Acquisition Cost (WAC) pricing for Pharmaceutical Drugs in the US. The main goal is to increase transparency and promote affordability in the pharmaceutical industry. The state agencies aim to provide consumers and healthcare providers with more information about the prices of prescription drugs.
The scope of what manufacturers must be aware of and report on has never been larger and more complicated which certainly doesn’t show any signs of slowing down. Manufacturers need to have a baseline understanding and be aware of which states have regulations, what they should be considering for certain scenarios, and considerations for actions like price increases and drug launches. Staying compliant requires a lot of detailed knowledge to stay proactive and be compliant with the states.
State Price Transparency Reporting Challenges
IntegriChain Supports Pharmaceutical Manufacturers with State Price Transparency Reporting services that include:
Build out Contract and Pricing Solutions
In 2022, we’ve identified four key trends as states refine their processes: dedicated portals, registration fees, maintenance requirements, and continuous updates.
Read the Blog
In this post, we’ll explore the best practice recommendations regarding compliance for SPTR.
